Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced that it will conduct a conference call on Tuesday, December 8, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss new clinical data from ongoing clinical trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer. The data, which include additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive metastatic breast cancer, as well as an analysis of patients who suffer from central nervous system (CNS) metastases, are slated for presentation during the San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.
To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon’s website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
CONTACT: Investor Relations: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Media Relations: Kelly France, Ph.D. BrewLife 415-946-1076 [email protected]
